Multiple Sclerosis - Pipeline Review - H1 2014





Published: March 2014 | Pages: 648 | Format: PDF

 Summary 

 Global Markets Direct’s, ‘Multiple Sclerosis - Pipeline Review, H1 2014’, provides an overview of the Multiple Sclerosis’s therapeutic pipeline. 

 This report provides comprehensive information on the therapeutic development for Multiple Sclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Sclerosis and special features on late-stage and discontinued projects. 

 Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. 

 The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. 

 Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. 

 Scope 

 

  •  The report provides a snapshot of the global therapeutic landscape of Multiple Sclerosis 
  •  The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities  
  •  The report reviews key players involved in the therapeutics development for Multiple Sclerosis and enlists all their major and minor projects 
  •  The report summarizes all the dormant and discontinued pipeline projects  
  •  A review of the Multiple Sclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
  •  Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
  •  A detailed assessment of monotherapy and combination therapy pipeline projects 
  •  Coverage of the Multiple Sclerosis pipeline on the basis of target, MoA, route of administration and molecule type 
  •  Latest news and deals relating related to pipeline products 

 

 Reasons to buy 

 

  •  Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies 
  •  Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
  •  Develop strategic initiatives by understanding the focus areas of leading companies 
  •  Identify and understand important and diverse types of therapeutics under development for Multiple Sclerosis 
  •  Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline 
  •  Devise corrective measures for pipeline projects by understanding Multiple Sclerosis pipeline depth and focus of Indication therapeutics 
  •  Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope 
  •  Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline 

 

 Introduction 8 

 Multiple Sclerosis Overview 9 

 Therapeutics Development 10 

 Multiple Sclerosis - Therapeutics under Development by Companies 12 

 Multiple Sclerosis - Therapeutics under Investigation by Universities/Institutes 25 

 Multiple Sclerosis - Pipeline Products Glance 28 

 Multiple Sclerosis - Products under Development by Companies 32 

 Multiple Sclerosis - Products under Investigation by Universities/Institutes 45 

 Multiple Sclerosis - Companies Involved in Therapeutics Development 47 

 Multiple Sclerosis - Therapeutics Assessment 186 

 Drug Profiles 209 

 Multiple Sclerosis - Recent Pipeline Updates 519 

 Multiple Sclerosis - Dormant Projects 602 

 Multiple Sclerosis - Discontinued Products 612 

 Multiple Sclerosis - Product Development Milestones 613 

 Appendix 620 

  

 List of Tables 

 Number of Products under Development for Multiple Sclerosis, H1 2014 37 

 Number of Products under Development for Multiple Sclerosis - Comparative Analysis, H1 2014 38 

 Number of Products under Development by Companies, H1 2014 40 

 Number of Products under Development by Companies, H1 2014 (Contd..1) 41 

 Number of Products under Development by Companies, H1 2014 (Contd..2) 42 

 Number of Products under Development by Companies, H1 2014 (Contd..3) 43 

 Number of Products under Development by Companies, H1 2014 (Contd..4) 44 

 Number of Products under Development by Companies, H1 2014 (Contd..5) 45 

 Number of Products under Development by Companies, H1 2014 (Contd..6) 46 

 Number of Products under Development by Companies, H1 2014 (Contd..7) 47 

 Number of Products under Development by Companies, H1 2014 (Contd..8) 48 

 Number of Products under Development by Companies, H1 2014 (Contd..9) 49 

 Number of Products under Development by Companies, H1 2014 (Contd..10) 50 

 Number of Products under Development by Companies, H1 2014 (Contd..11) 51 

 Number of Products under Investigation by Universities/Institutes, H1 2014 53 

 Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 54 

 Comparative Analysis by Late Stage Development, H1 2014 55 

 Comparative Analysis by Clinical Stage Development, H1 2014 56 

 Comparative Analysis by Early Stage Development, H1 2014 57 

 Comparative Analysis by Unknown Stage Development, H1 2014 58 

 Products under Development by Companies, H1 2014 59 

 Products under Development by Companies, H1 2014 (Contd..1) 60 

 Products under Development by Companies, H1 2014 (Contd..2) 61 

 Products under Development by Companies, H1 2014 (Contd..3) 62 

 Products under Development by Companies, H1 2014 (Contd..4) 63 

 Products under Development by Companies, H1 2014 (Contd..5) 64 

 Products under Development by Companies, H1 2014 (Contd..6) 65 

 Products under Development by Companies, H1 2014 (Contd..7) 66 

 Products under Development by Companies, H1 2014 (Contd..8) 67 

 Products under Development by Companies, H1 2014 (Contd..9) 68 

 Products under Development by Companies, H1 2014 (Contd..10) 69 

 Products under Development by Companies, H1 2014 (Contd..11) 70 

 Products under Development by Companies, H1 2014 (Contd..12) 71 

 Products under Investigation by Universities/Institutes, H1 2014 72 

 Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 73 

 Multiple Sclerosis - Pipeline by Biogen Idec Inc., H1 2014 74 

 Multiple Sclerosis - Pipeline by Amgen Inc., H1 2014 75 

 Multiple Sclerosis - Pipeline by Athersys, Inc., H1 2014 76 

 Multiple Sclerosis - Pipeline by GlaxoSmithKline plc, H1 2014 77 

 Multiple Sclerosis - Pipeline by MedImmune, LLC, H1 2014 78 

 Multiple Sclerosis - Pipeline by Biotest AG, H1 2014 79 

 Multiple Sclerosis - Pipeline by Alkermes Plc, H1 2014 80 

 Multiple Sclerosis - Pipeline by Merck & Co., Inc., H1 2014 81 

 Multiple Sclerosis - Pipeline by AbGenomics International, Inc., H1 2014 82 

 Multiple Sclerosis - Pipeline by Plexxikon Inc., H1 2014 83 

 Multiple Sclerosis - Pipeline by Apitope International NV, H1 2014 84 

 Multiple Sclerosis - Pipeline by Hanwha Chemical Corporation, H1 2014 85 

 Multiple Sclerosis - Pipeline by Aphios Corporation, H1 2014 86 

 Multiple Sclerosis - Pipeline by Acorda Therapeutics, Inc., H1 2014 87 

 Multiple Sclerosis - Pipeline by Biocon Limited, H1 2014 88 

 Multiple Sclerosis - Pipeline by Eisai Co., Ltd., H1 2014 89 

 Multiple Sclerosis - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2014 90 

 Multiple Sclerosis - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2014 91 

 Multiple Sclerosis - Pipeline by Pfizer Inc., H1 2014 92 

 Multiple Sclerosis - Pipeline by Rigel Pharmaceuticals, Inc., H1 2014 93 

 Multiple Sclerosis - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2014 94 

 Multiple Sclerosis - Pipeline by Zydus Cadila Healthcare Limited, H1 2014 95 

 Multiple Sclerosis - Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2014 96 

 Multiple Sclerosis - Pipeline by Exelixis, Inc., H1 2014 97 

 Multiple Sclerosis - Pipeline by Paratek Pharmaceuticals, Inc., H1 2014 98 

 Multiple Sclerosis - Pipeline by Celgene Corporation, H1 2014 99 

 Multiple Sclerosis - Pipeline by OPKO Health, Inc., H1 2014 100 

 Multiple Sclerosis - Pipeline by BrainStorm Cell Therapeutics Inc., H1 2014 101 

 Multiple Sclerosis - Pipeline by 4SC AG, H1 2014 102 

 Multiple Sclerosis - Pipeline by Addex Therapeutics, H1 2014 103 

 Multiple Sclerosis - Pipeline by Evotec AG, H1 2014 104 

 Multiple Sclerosis - Pipeline by Hemispherx Biopharma, Inc., H1 2014 105 

 Multiple Sclerosis - Pipeline by Harbor Therapeutics, Inc., H1 2014 106 

 Multiple Sclerosis - Pipeline by Neuralstem, Inc., H1 2014 107 

 Multiple Sclerosis - Pipeline by Antisense Therapeutics Limited, H1 2014 108 

 Multiple Sclerosis - Pipeline by Idera Pharmaceuticals, Inc., H1 2014 109 

 Multiple Sclerosis - Pipeline by Karo Bio AB, H1 2014 110 

 Multiple Sclerosis - Pipeline by Almirall, S.A., H1 2014 111 

 Multiple Sclerosis - Pipeline by Lpath, Inc., H1 2014 112 

 Multiple Sclerosis - Pipeline by Bionomics Limited, H1 2014 113 

 Multiple Sclerosis - Pipeline by MultiCell Technologies, Inc., H1 2014 114 

 Multiple Sclerosis - Pipeline by Catalyst Pharmaceutical Partners, Inc., H1 2014 115 

 Multiple Sclerosis - Pipeline by Nutra Pharma Corporation, H1 2014 116 

 Multiple Sclerosis - Pipeline by Compugen Ltd., H1 2014 117 

 Multiple Sclerosis - Pipeline by Critical Outcome Technologies Inc., H1 2014 118 

 Multiple Sclerosis - Pipeline by Acadia Pharmaceuticals Inc., H1 2014 119 

 Multiple Sclerosis - Pipeline by Accentia Biopharmaceuticals, Inc., H1 2014 120 

 Multiple Sclerosis - Pipeline by Arena Pharmaceuticals, Inc., H1 2014 121 

 Multiple Sclerosis - Pipeline by RegeneRx Biopharmaceuticals, Inc., H1 2014 122 

 Multiple Sclerosis - Pipeline by ProMetic Life Sciences Inc., H1 2014 123 

 Multiple Sclerosis - Pipeline by Xenetic Biosciences plc, H1 2014 124 

 Multiple Sclerosis - Pipeline by HanAll Biopharma Co., Ltd., H1 2014 125 

 Multiple Sclerosis - Pipeline by Cytos Biotechnology AG, H1 2014 126 

 Multiple Sclerosis - Pipeline by LG Life Sciences, Ltd., H1 2014 127 

 Multiple Sclerosis - Pipeline by Pluristem Therapeutics Inc., H1 2014 128 

 Multiple Sclerosis - Pipeline by Resverlogix Corp., H1 2014 129 

 Multiple Sclerosis - Pipeline by Sareum Holdings plc, H1 2014 130 

 Multiple Sclerosis - Pipeline by Transgene Biotek Limited, H1 2014 131 

 Multiple Sclerosis - Pipeline by Shenzhen Beike Biotechnology Co., Ltd., H1 2014 132 

 Multiple Sclerosis - Pipeline by Morphotek, Inc., H1 2014 133 

 Multiple Sclerosis - Pipeline by Digna Biotech, S.L., H1 2014 134 

 Multiple Sclerosis - Pipeline by Antitope Ltd., H1 2014 135 

 Multiple Sclerosis - Pipeline by Axxam SpA, H1 2014 136 

 Multiple Sclerosis - Pipeline by Pieris AG, H1 2014 137 

 Multiple Sclerosis - Pipeline by Hutchison MediPharma Limited, H1 2014 138 

 Multiple Sclerosis - Pipeline by Trophos SA, H1 2014 139 

 Multiple Sclerosis - Pipeline by Argos Therapeutics, Inc., H1 2014 140 

 Multiple Sclerosis - Pipeline by Affectis Pharmaceuticals AG, H1 2014 141 

 Multiple Sclerosis - Pipeline by Coronado Biosciences, Inc., H1 2014 142 

 Multiple Sclerosis - Pipeline by MacroGenics, Inc., H1 2014 143 

 Multiple Sclerosis - Pipeline by Q Therapeutics, Inc., H1 2014 144 

 Multiple Sclerosis - Pipeline by Catabasis Pharmaceuticals, Inc., H1 2014 145 

 Multiple Sclerosis - Pipeline by Vaccinex, Inc., H1 2014 146 

 Multiple Sclerosis - Pipeline by Kineta, Inc., H1 2014 147 

 Multiple Sclerosis - Pipeline by MSM Protein Technologies, Inc., H1 2014 148 

 Multiple Sclerosis - Pipeline by Vascular Biogenics Ltd., H1 2014 149 

 Multiple Sclerosis - Pipeline by Endocyte, Inc., H1 2014 150 

 Multiple Sclerosis - Pipeline by Theraclone Sciences, Inc., H1 2014 151 

 Multiple Sclerosis - Pipeline by Effimune SAS, H1 2014 152 

 Multiple Sclerosis - Pipeline by Siena Biotech S.p.A., H1 2014 153 

 Multiple Sclerosis - Pipeline by Virogenomics, Inc., H1 2014 154 

 Multiple Sclerosis - Pipeline by Omeros Corporation, H1 2014 155 

 Multiple Sclerosis - Pipeline by Bolder Biotechnology, Inc., H1 2014 156 

 Multiple Sclerosis - Pipeline by Aegis Therapeutics, LLC, H1 2014 157 

 Multiple Sclerosis - Pipeline by Cellceutix Corporation, H1 2014 158 

 Multiple Sclerosis - Pipeline by Biovista Inc., H1 2014 159 

 Multiple Sclerosis - Pipeline by SanBio, Inc., H1 2014 160 

 Multiple Sclerosis - Pipeline by KaloBios Pharmaceuticals, Inc., H1 2014 161 

 Multiple Sclerosis - Pipeline by Provid Pharmaceuticals, Inc., H1 2014 162 

 Multiple Sclerosis - Pipeline by Vitae Pharmaceuticals, Inc., H1 2014 163 

 Multiple Sclerosis - Pipeline by Biokine Therapeutics Ltd., H1 2014 164 

 Multiple Sclerosis - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2014 165 

 Multiple Sclerosis - Pipeline by OncoImmune, Inc., H1 2014 166 

 Multiple Sclerosis - Pipeline by to-BBB technologies BV, H1 2014 167 

 Multiple Sclerosis - Pipeline by PharmaEssentia Corporation, H1 2014 168 

 Multiple Sclerosis - Pipeline by KAHR medical Ltd., H1 2014 169 

 Multiple Sclerosis - Pipeline by M's Science Corporation, H1 2014 170 

 Multiple Sclerosis - Pipeline by Phenomenome Discoveries, Inc., H1 2014 171 

 Multiple Sclerosis - Pipeline by Lycera Corp., H1 2014 172 

 Multiple Sclerosis - Pipeline by MAKScientific, LLC, H1 2014 173 

 Multiple Sclerosis - Pipeline by RhinoCyte, Inc., H1 2014 174 

 Multiple Sclerosis - Pipeline by Vakzine Projekt Management GmbH, H1 2014 175 

 Multiple Sclerosis - Pipeline by Pfenex Inc., H1 2014 176 

 Multiple Sclerosis - Pipeline by Vicore Pharma AB, H1 2014 177 

 Multiple Sclerosis - Pipeline by Cellmid Limited, H1 2014 178 

 Multiple Sclerosis - Pipeline by Varinel, Inc., H1 2014 179 

 Multiple Sclerosis - Pipeline by Cognosci, Inc., H1 2014 180 

 Multiple Sclerosis - Pipeline by Immune Technologies and Medicine GmbH, H1 2014 181 

 Multiple Sclerosis - Pipeline by Targazyme, Inc., H1 2014 182 

 Multiple Sclerosis - Pipeline by Nectid, Inc., H1 2014 183 

 Multiple Sclerosis - Pipeline by ProNoxis AB, H1 2014 184 

 Multiple Sclerosis - Pipeline by Nuron Biotech, Inc., H1 2014 185 

 Multiple Sclerosis - Pipeline by Cell Cure Neurosciences, Ltd., H1 2014 186 

 Multiple Sclerosis - Pipeline by GeNeuro SA, H1 2014 187 

 Multiple Sclerosis - Pipeline by VivaCell Biotechnology Espana S.L., H1 2014 188 

 Multiple Sclerosis - Pipeline by Forward Pharma A/S, H1 2014 189 

 Multiple Sclerosis - Pipeline by Genervon Biopharmaceuticals, LLC, H1 2014 190 

 Multiple Sclerosis - Pipeline by Regenesance BV, H1 2014 191 

 Multiple Sclerosis - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2014 192 

 Multiple Sclerosis - Pipeline by BRAINco Biopharma, S.L., H1 2014 193 

 Multiple Sclerosis - Pipeline by SOM Biotech SL, H1 2014 194 

 Multiple Sclerosis - Pipeline by Immune Response BioPharma, Inc., H1 2014 195 

 Multiple Sclerosis - Pipeline by Bionure Farma, S.L., H1 2014 196 

 Multiple Sclerosis - Pipeline by IntelliCell BioSciences Inc., H1 2014 197 

 Multiple Sclerosis - Pipeline by International Biotechnology Center Generium, H1 2014 198 

 Multiple Sclerosis - Pipeline by Visionary Pharmaceuticals, Inc., H1 2014 199 

 Multiple Sclerosis - Pipeline by Arrien Pharmaceuticals, LLC, H1 2014 200 

 Multiple Sclerosis - Pipeline by CalAsia Pharmaceuticals, Inc., H1 2014 201 

 Multiple Sclerosis - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2014 202 

 Multiple Sclerosis - Pipeline by Sage Therapeutics, H1 2014 203 

 Multiple Sclerosis - Pipeline by Lanthio Pharma B.V., H1 2014 204 

 Multiple Sclerosis - Pipeline by ReveraGen BioPharma, Inc., H1 2014 205 

 Multiple Sclerosis - Pipeline by Biomar Microbial Technologies, H1 2014 206 

 Multiple Sclerosis - Pipeline by ImmuNext, Inc., H1 2014 207 

 Multiple Sclerosis - Pipeline by Toleranzia AB, H1 2014 208 

 Multiple Sclerosis - Pipeline by XL-protein GmbH, H1 2014 209 

 Multiple Sclerosis - Pipeline by Glialogix, Inc., H1 2014 210 

 Multiple Sclerosis - Pipeline by Bionature E.A. Ltd., H1 2014 211 

 Multiple Sclerosis - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2014 212 

 Assessment by Monotherapy Products, H1 2014 213 

 Assessment by Combination Products, H1 2014 214 

 Number of Products by Stage and Target, H1 2014 217 

 Number of Products by Stage and Mechanism of Action, H1 2014 224 

 Number of Products by Stage and Route of Administration, H1 2014 232 

 Number of Products by Stage and Molecule Type, H1 2014 235 

 Multiple Sclerosis Therapeutics - Recent Pipeline Updates, H1 2014 546 

 Multiple Sclerosis - Dormant Projects, H1 2014 629 

 Multiple Sclerosis - Dormant Projects (Contd..1), H1 2014 630 

 Multiple Sclerosis - Dormant Projects (Contd..2), H1 2014 631 

 Multiple Sclerosis - Dormant Projects (Contd..3), H1 2014 632 

 Multiple Sclerosis - Dormant Projects (Contd..4), H1 2014 633 

 Multiple Sclerosis - Dormant Projects (Contd..5), H1 2014 634 

 Multiple Sclerosis - Dormant Projects (Contd..6), H1 2014 635 

 Multiple Sclerosis - Dormant Projects (Contd..7), H1 2014 636 

 Multiple Sclerosis - Dormant Projects (Contd..8), H1 2014 637 

 Multiple Sclerosis - Dormant Projects (Contd..9), H1 2014 638 

 Multiple Sclerosis - Discontinued Products, H1 2014 639 

  

 List of Figures 

 Number of Products under Development for Multiple Sclerosis, H1 2014 37 

 Number of Products under Development for Multiple Sclerosis - Comparative Analysis, H1 2014 38 

 Number of Products under Development by Companies, H1 2014 39 

 Number of Products under Investigation by Universities/Institutes, H1 2014 52 

 Comparative Analysis by Late Stage Development, H1 2014 55 

 Comparative Analysis by Clinical Stage Development, H1 2014 56 

 Comparative Analysis by Early Stage Products, H1 2014 57 

 Assessment by Monotherapy Products, H1 2014 213 

 Assessment by Combination Products, H1 2014 214 

 Number of Products by Top 10 Target, H1 2014 215 

 Number of Products by Stage and Top 10 Target, H1 2014 216 

 Number of Products by Top 10 Mechanism of Action, H1 2014 222 

 Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 223 

 Number of Products by Top 10 Route of Administration, H1 2014 230 

 Number of Products by Stage and Top 10 Route of Administration, H1 2014 231 

 Number of Products by Top 10 Molecule Type, H1 2014 233 

 Number of Products by Stage and Top 10 Molecule Type, H1 2014 234